NKA Bio is developing new medicines to press pause on death and buy more time for life-saving care
About NKA Bio
Who:
NKA Bio is a biotech startup founded based on research by the 1st Director of Emergency Medicine at Johns Hopkins.
What:
NKA Bio is developing new medicines for critically ill patients that press pause on death and buy more time for life saving care.
Where:
NKA Bio operates R&D facilities in Baltimore, Maryland Equipped for Antibody Engineering and Assay Development
When:
NKA01 is <18 months from clinic with the right funding and support.
The Problem
Contrary to popular belief, people don't die from car crashes or gun shots.
People die from their body's response to the injury, a state known as shock.
Shock is the #1 Cause of Death for People Ages 1 - 44 in the United States
Every Year in addition to the 90,000 trauma patients who don't live long enough to get to a hospital...
Our Solution
Introducing NKA01
When minutes count, our antibody buys hours. NKA01 presses pause on death with a low-volume injection at the point of injury to buy more time for transport and lifesaving surgery.
Product:
Prefilled Syringe with our Anti-Shock Toxin Antibody for Injection by EMS during their standard treatment protocols to prepare the patient for transport.
Key Features:
Temperature stable and low volume for field use by EMS to immediately stabilize trauma patients and press pause on death to buy more time for transport to a trauma center for care.
Progress to Date:
Proof of Concept In Vivo with a Prototype. Lead Candidate Selected.
Pipeline
World Health Organization
Team
Donald S. Gann, MD
(1932 - 2020)
Scientific Founder
Dr. Gann was a pioneer and leader in trauma care and biomedical engineering, serving as the first Director of Emergency Medicine at Johns Hopkins and the first Chair of Biomedical Engineering at Case Western Reserve. A polymath with a background in physics, philosophy, and medicine, Dr. Gann's life work was improving outcomes for trauma patients. From his lab to the operating room, Dr. Gann was a leader in trauma care and research, serving as the 18th President of the American Association for the Surgery of Trauma and publishing >250 peer reviewed papers - a body of work which ultimately led to the science at the heart of NKA Bio's Shock Pipeline
Susan Gann Hibbs
Co-Founder & Executive Chair
Susan leads the vision of the company as Chairwoman and co-founder. She works with key advisors to guide pipeline strategy, and supports key operational areas day to day, including finance and human resources.
Lewis C. Hibbs III
Co-Founder &
CEO
Lewis developed NKA Bio's Smol mAb Platform fueling NKA Bio's antibody discovery. He leads R&D and operates NKA Bio day-to-day. Lewis is the PI on $1.3M+ in DoD contracts advancing NKA Bio's drug pipeline.
Elizabeth
Zuerblis, MSE
Research Associate
BioEngineering
Michael
Sweet, MSE
Research Associate
Process Engineering
KEY SUPPORTERS
